Table 7.
Number of KIR genes and KIR/HLA-I combinations in patients with AML compared to controls.
| No. of KIR genes | AML: n = 181 (%) | Control: n = 181 (%) | P-value OR (95% CI) |
|---|---|---|---|
| ≥ 4 aKIRs | 85 (46.9) | 67 (37.0) | 0.055 |
| ≥ 4 iKIRs | 123 (67.9) | 119 (65.8) | 0.65 |
| iKIRs > aKIRs | 102 (56.4) | 116 (64.1) | 0.13 |
| aKIRs > iKIRs | 39 (21.5) | 28 (15.5) | 0.13 |
| No. of KIR/HLA combination | |||
| ≥ 3 aKIRs/HLA | 17 (9.4) | 21 (11.6) | 0.49 |
| ≥ 3 iKIRs/HLA | 102 (56.4) | 140 (77.4) | 0.00002 |
| 0.37 (0.23–0.59) | |||
| iKIRs/HLA > aKIRs/HLA | 150 (82.9) | 161 (89.0) | 0.09 |
| aKIRs/HLA > iKIRs/HLA | 3 (1.7) | 2 (1.1) | 0.99‡ |
| iKIRs/HLA = aKIRs/HLA | 28 (15.5) | 18 (9.9) | 0.11 |
The Chi-square test was done based on a 2 × 2 contingency table, p < 0.05 was considered significant. OR: odds ratio, CI: confidence interval.
‡p-value with Yates’ correction.
Significant values are in bold.